News

The first book written for public at large about medicines has been presented in Moscow. The authors, brought together by Vladislav Dorofeev, a well-known journalist and writer, collected facts and wrote their stories of the inventions and discoveries of ether and aspirin, haloperidol and smallpox vaccine, penicillin and Prozac, Viagra and Herceptin, hydrocortisone and cocaine, Losec and vitamins, insulin and lidocaine, and many others. By telling all these stories in an entertaining way, and invariably keeping true to the facts, the authors were not only able to take readers on a fascinating journey into the history and the present day of the drugs in our medicine box, but also provided an insight into pharmacy.

Representatives of international pharmaceutical industry shared their vision towards the solutions of key problems of the Russian pharmaceutical market and discussed the most important priorities for its further development.

June 17, 2014, St. Petersburg — As part of the 20th Russian Pharmaceutical Forum, the Association of International Pharmaceutical Manufacturers (AIPM), which is also celebrating its 20th anniversary this year, has initiated a discussion of the most pressing issues for today's pharmaceutical market, including the prospects for development of healthcarein the Russian Federation, increasing the innovative potential of local pharmaceutical industry, improving the regulatory system, building a modern drug provision system, etc.

March 28, 2014, Moscow – Association of International Pharmaceutical Manufacturers (AIPM) announces extension of the member list. On March 26, 2014 during the General Meeting of AIPM members it was decided that international pharmaceutical company Allergan join the Association.

The Association of International Pharmaceutical Manufacturers (AIPM) together with the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) released the findings of an analytical research on corporate healthy lifestyle practices at Russian and global companies and provide recommendations on the development and implementation of such programs.

Collaboration

Five global healthcare organizations have established a Consensus Framework for Ethical Collaboration to support partnerships that will aim to deliver greater patient benefits and support high quality patient care. Derived from the individual codes of ethical practice and health policy positions of the five supporting organizations, this framework is based on four overarching principles:

23 January 2014, Moscow – Association of International Pharmaceutical Manufacturers (AIPM) announces that Mrs. Naira Adamian, Managing Director of Pharma division of “Johnson and Johnson” Russia & CIS, has been appointed the Chairman of the Board of Directors      

December 13, 2013, Moscow - The Association of International Pharmaceutical Manufacturers (AIPM) announces extension of the member list. On December 4, 2013 during the General Meeting of AIPM members it was decided that international pharmaceutical companies Alexion, Ferring Pharmaceuticals and Gilead Sciences join the Association.

Moscow, May 16,2013. Today several countries have regulatory requirements in place for the development and evaluation of biotherapeutic and biosimilar medicines. The European Union, for example, provides unified standards and guidelines that are effective in the entire region. In Russia, on the contrary, these topics are not yet regulated. This is one of the key points that international and Russian experts are discussing in the context of the two-day workshop Biotherapeutic Medicines – Regulatory Challenges and Current Practices. Approaches for Harmonization.

April 1, 2013, Moscow – The Association of International Pharmaceutical Manufacturers announces extension of the Association member list. On March 27, 2013 the General Meeting of AIPM members decided on the membership of R-Pharm Group. It is an important achievement for the Russian pharmaceutical market confirming the inconvertibility of partnership between Russian and international pharmaceutical companies and their further integration.

Draft documents limiting the state purchases of foreign medication do not take into account the Russian Federation citizens’ rights for affordable and high-quality treatment. It has been announced by the participants of the press conference devoted to the discussion on the draft RF Government Decree “On introducing additional requirements to order placement participants in case of placing orders for the provision of medications" and draft Law prepared by the Ministry of Industry and Trade of Russia and devoted to the criteria in accordance to which medications can be attributed to medicinal products of the Russian origin.

The world-famous Prix Galien Prize, created in France in 1970, is the most prestigious prize in biotechnologies and the pharmaceutical industry, which is annually awarded for outstanding achievements in the development of innovative treatment methods and technologies. The Galien Foundation has now decided to include Russia in the list of host countries for the competition, beginning from 2013.

25 April 2012, Moscow. – The Institute of Legislation and Comparative Law under the Government of the Russian Federation presented Legal Opinion on the topic ‘Legal Aspects of Interaction between Pharmaceutical Company Representatives and Healthcare Professionals’. This Legal Opinion was prepared with the support of the Association of International Pharmaceutical Manufacturers (AIPM).

On March 19, 2012, Pharmatsevtichenskiy vestnik (Pharmaceutical bulletin) newspaper and “Pharmexpert” Market Research Centre announced the most influential entities of the Russian pharmaceutical market in 2011. The annual review, which has been conducted more than 10 years, surveys independent market experts across various areas to rank influence in the Russian healthcare industry. Based on the answers provided by peers and industry experts, AIPM was named the Most Influential Non-Profit and Public Association by a wide margin.

All over the world February, 29 was marked as International Rare Disease Day - when the organizations active in the field of rare diseases and their partners join forces to raise awareness of society on problems of millions of people living with orphan diseases. Association of International Pharmaceutical Manufacturers (AIPM) partners with the international non-governmental patient-driven alliance EURORDIS and contributes to the communication to the Russian patients, doctors, and other stakeholders with the Russian version of web resource www.eurordis.org/ru

MOSCOW, November 1, 2011 The Association of International Pharmaceutical Manufacturers (AIPM) actively participates in the work of “The Council of Europe Convention on Counterfeiting of Medical Products and Similar Crimes Involving Threats to Public Health (Medicrime Convention)”, High Level International Conference held in Moscow on October 26 - 28, 2011.

May 17, 2011, Saint-Petersburg. Association of International Pharmaceutical Manufacturers (AIPM) believes that the introduction of the proposed wording of the Article 69 of the Federal law draft “On bases of health protection of citizens of the Russian Federation” can cause serious damage to Russian healthcare. This opinion was expressed during the Russian Pharmaceutical Forum of Adam Smith Institute.

The results of AIPM research show an insufficient level of diagnosis and low awareness of their personal health.

The Association of International Pharmaceutical Manufacturers (AIPM) supported by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) conducted a survey entitled Population Attitude to Personal Health: Perception of Health, Understanding of Risk Factors, Morbidity and Mortality in Russia. The findings will be presented on the eve of the WHO Global Forum: Addressing the Challenge of Non-communicable Diseases (NCD) and the First Global Ministerial Conference on Healthy Lifestyles and Non-communicable Disease Control, which will be held in Moscow on April 27, 28 and 29, 2011, under the auspices of the World Health Organization (WHO) and the Russian Federation.

Eisai, Galderma, Macleods and Takeda were admitted to membership in the Association of International Pharmaceutical Manufacturers (AIPM) at a General Meeting of Members of the Association.

Novartis AG is planning to build a 2-billion-units plant in the territory of a pharmaceutical cluster in Saint-Petersburg. The level of investment will make up 500 billion dollars within the next 5 years.